This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Multiple myeloma
  • /
  • Panobinostat for the management of multiple myelom...
Journal

Panobinostat for the management of multiple myeloma.

Read time: 1 mins
Published:1st Mar 2017
Author: Sivaraj D, Green MM, Gasparetto C.
Source: Future Oncology
Availability: Pay for access, or by subscription
Ref.:Future Oncol. 2017;13(6):477-488.
DOI:10.2217/fon-2016-0329

Multiple myeloma (MM) is the second most common blood cancer following non-Hodgkin's lymphoma. While the treatments for MM have improved over the past decade, for the most part, it remains an incurable disease. For this reason newer therapeutic agents are needed to combat this malignancy. Panobinostat is a pan-deacetylase inhibitor that impedes protein destruction by disturbing the enzymatic activity of deacetylases. It was US FDA approved in February 2015 for the management of relapsed/refractory MM in combination with bortezomib and dexamethasone. Several trials are ongoing, exploring the utility of panobinostat in various other settings for the management of MM.

This review will detail the biology, clinical efficacy and potential future applications of panobinostat in the treatment of MM.

 

Read abstract on library site

Access full article